A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Launched by CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD · May 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Purinostat mesylate for patients with a type of cancer known as diffuse large B-cell lymphoma (DLBCL) that has either come back after treatment or has not responded to previous therapies. The main goal is to see how effective Purinostat mesylate is compared to another treatment called selinexor in helping patients get better and live longer. Participants in the trial will receive either the Purinostat mesylate through an IV four times every three weeks or take selinexor by mouth twice a week for four weeks.

To be eligible for this study, participants must be at least 18 years old and have been diagnosed with DLBCL that hasn’t responded to at least two previous treatments. They need to have measurable disease and good overall health. However, people who are pregnant, have had certain types of previous cancer treatments, or have serious infections are not allowed to participate. This trial is not yet recruiting participants, so there will be more information available soon for those who might be interested in joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years, no gender restrictions;
• • 2. Histologically-confirmed DLBCL, Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy (2-5 lines);
• • 3. Participants must have measurable disease;
• • 4. ECOG≤2;
• • 5. Adequate organ function
• Exclusion Criteria:
• • 1. Pregnancy or breastfeeding;
• • 2. Previous history of transplantation;
• • 3. Double/Triple Hit B cell lymphoma;
• • 4. Patient with known active infection, or reactivation of a latent infection;
• • 5. Any serious diseases that investigator deems inappropriate to participate.